Miller, R.G. 1980. An immunological suppressor cell inactivating cytotoxic T lymphocyte precursor cells recognizing it. Nature 287: 544–546
Rammensee, H.-G., Nagy, Z.A. and Klein, J. 1982. Suppression of cell-mediated lymphotoxicity against minor histocompatibility antigens mediated by Ly 1+ Ly 2+ T cells of stimulator strain origin. Eur. J. Immunol. 12: 930–934
Fink, P.J., Weissman, I.L. and Bevan, M.J. 1983. Haplotype specific suppression of cytotoxic T cell induction by antigen inappropriately presented on T cells . J. Exp.Med. 157: 141–154
Hambar, J.E., Kaplan, D.R. and Tykocinski, M.L. 1990. CD8 functions as inhibitory ligand in mediating the immunoregulaory activity of CD8+ cells. J. Immunol. 12: 930–934
Sambhara, S., and Miller, R.G. 1991. Programmed cell death of T cells signaled by theTcell receptor and the α, domain of class I MHC. Science. 252:1424–1427
Rammensee, H.-G. 1989. Veto function in vitro and in vivo. Int. Rev. Immunol. 4: 175–191
Martin, D.R., and Milter, R.G. 1989. In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors. J. Exp. Med. 170: 679–690
Rammensee, H.-G., Juretic, A., Nagy, Z.A., and Klein, J. 1984. Class l-restricted interaction between suppressor and cytolytic cells in the response to minor histocompatibility antigens. J. Immunol. 132: 668–672
Zhang, L., Shannon, J., Sheldon, J., Teh, H.-S., Mak, T.W. and Miller, R.G. 1994. Role of infused CD8- cells in the induction of peripheral tolerance. J. Immunol. 152: 2221–2228
Johnson, L.L. 1987. Prolonged minor allograft survival of intravenously primed mice-a test of the veto hypothesis. Transplantation 44: 92–97
Thomas, J.M., Carver, F.M., Cunningham, P.R., Oison, L.C., and Thomas, F.T. 1991. Kidney allograft tolerance in primates without chronic immunosuppression. Transplant. Proc. 23: 11–13
Takahashi, T., and Maki, H. 1991. Prolongation of mouse skin allograft survival by cloned veto suppressor cells. Transplant. Proc. 23: 192–193
Hiruma, K., Nakamura, H., Henkart, P.A. and Gress, R.E. 1992. Clonal deletion of postthymic T cells: Veto cells kill precursor cytotoxic T lymphocytes. J. Exp. Med. 175: 863–868
Thomas, J.M., Carver, P.M., Kasten-Jolly, J., Haisch, C.E., Rebellato, L.M., Gross, U. et al. 1994. Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation. 57: 101–115.
Rotzschke, O., Falk, K., Faath, S. and Rammensee, H.-G. 1991. On the nature of peptides involved in T cell alloreactivity. J. Exp. Med. 174: 1059–1071.
Matis LA., Sorger, S.B., McElligott, D.L., Fink, RJ and Hedrick, S.M. 1987. The molecular basis of alloreactivity in antigen-specific, major histocompatibility complex-restricted T cell clones. Cell 51: 59–69.
Liu, Z., Sun, Y.K., Xi, Y.P., Maffei, A., Reed, E., Harris, P. et al. 1994. Contribution of direct and indirect recognition pathways to T cell alloreactivity. J. Exp. Med. 177: 1643–1650
Fangmann, J., Dalchau, R. and Fabre, J.W. 1992. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex pep-tides. J. Exp. Med. 175: 1521–1529
Hambor, J.E., Weber, M.C., Tykocinski, M.L. and Kaplan, D.R. 1990. Regulation of allogeneic responses by expression of CD8 α-chain on stimulator cells. Intern. Immunol. 2: 879–883.
Rosenberg, A.S. and Singer, A. 1992. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu. Rev. Immunol. 10: 333–358
Cobbold, S. and Waldmann, H. 1986. Skin allograft rejection by L3T4+ and Lyt-2+ T cell subsets. Transplantation 41: 634–639
Mizuochi, T., Goldlng, H., Rosenberg, A.S., Glimcher, L.H., Malek, T.R. and Singer, A. 1985. Both L3T4+ and Lyt-2+ T cells initiate cytotoxic T lymphocyte responses against allogeneic major histocompatibility antigens but not against trinitrophenyl-modified self. J. Exp. Med. 162: 427–143
Nepom, G.T. and Erlich, H. 1991. MHC class-ll molecules and autoimmunity.Annu. Rev. Immunol. 9: 493–525
O'Garra, A. and Murphy, K. T-cell subsets in autoimmunity. Curr. Opinion Immuno. 5: 880–886 1993.
Qi, Y., Berg, R., Singleton, M.A., Debrick, J.E. and Staerz, U.D. 1996. Hybrid antibody mediated veto of cytotoxic T lymphocyte responses. J. Exp. Med. 183: 1973–1980
Staerz, U.D., Kanagawa, O. and Bevan, M.J. 1983. Hybrid antibodies can target sites for attack by T cells. Nature 314: 628–631
Staerz, U.D. and Bevan, M.J. 1986. Hybrid hybridoma producing a bispecific monoclonal antibody which can focus T cell activity. Proc. Natl. Acad. Sci. USA 83: 1453–1457
Staerz, U.D., Yewdell, J.W. and Bevan, M.J. 1987.Hybrid antibody mediated lysis of virus infected cells. Eur. J. Immunol. 17: 571–574
Zepp, F. and Staerz, U.D. 1988. Hybrid antibodies induce selection processes in the thymus. Nature 336: 473–475
Traunecker, A., Lueke, W. and Karjalainen, K. 1988. Soluble CD4 molecules neutralize human immunodeficiency virus type I. Nature 331: 84–86
Ozato, K., Mayer, N. and Sachs, D.H. 1980. Hybridoma cell lines secreting monoclonal antibodies to mouse H–2 and la antigens. J. Immunol. 124: 533–540.
Mosmann, T.R. and Coffman, R.L. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.Annu. Rev. Immunol. 7: 145–179.
Smith, D.M., Bluestone, J.A., Newberg, M.K., Englehard, V.H., Thistlethwaite, J.R., and Woode, E.S. 1994. Inhibition of T cell activity by a monoclonal antibody directed against the alpha 3 domain of the Class I MHC molecule. J. Immunol. 153: 1054–1067.
Sprent, J. and Schaefer, M. 1990. Antigen-presenting cells for CD8+ T cells. [Review]. Immunol. Rev. 117: 213–234.
Kosaka, H., Surh, C.D. and Sprent, J. 1992. Stimulation of mature unprimed CD8+ T cells by semiprofessional antigen-presenting cells in vivo. J. Exp. Med. 176: 1291–1302.
Murphy, K.M., Heimberger, A.B. and Loh, D.Y. 1990. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250: 1720–1722.
Liu, C.P., Kappler, J.W. and Marrack, P. 1996. Thymocytes can become mature T cells without passing through the CD4+CD8+, double positive stage. J. Exp. Med. 184: 1619–1630
Steinman, R.M., Kaplan, G., Witmer, M.D. and Conn, Z.A. 1979. Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J. Exp. Med. 149:1–16.
Vella, A., Teague, T.K., Ihle, J., Kappler, J.W. and Marrack, R. 1997. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: State is probably not required for the effect of IL-4. J. Exp. Med. 186:325–330.